<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436292</url>
  </required_header>
  <id_info>
    <org_study_id>CE 10.239</org_study_id>
    <nct_id>NCT01436292</nct_id>
  </id_info>
  <brief_title>Hypoalbuminemia in Burn Patients</brief_title>
  <acronym>Halburns</acronym>
  <official_title>Hypoalbuminemia in Burn Patients: Should we Care? - A Randomized Controlled Clinical Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 5% human albumin solution, given to correct
      hypoalbuminemia, could improve organ dysfunction in burn patients as assessed by a change in
      the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or
      died).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year approximately 2 million people are burned in the USA, from which 80,000 are
      hospitalized and 6,500 die. It is a well known fact that the two most important factors for
      mortality in burn patients are age and percent total body surface area burn (TBSA), which are
      unmodifiable findings.

      A predictable inflammatory response takes place after a burn injury leading to profound
      changes in patient homeostasis. As a result, hypoalbuminemia is one of the common finding in
      severe burn patients. 21% of hospitalized adult patients are hypoalbuminemic on admission.
      After admission, worsening of existing hypoalbuminemia and development of de novo one are
      frequently seen.

      Moreover, hypoalbuminemia, a potentially modifiable variable, has been strongly associated
      with poor clinical outcomes in critically ill patients and in burn patients.

      Dynamic organ dysfunction scores have been introduced in critically ill patients few years
      ago in order to describe the evolution of patients on a daily basis. The Sequential Organ
      Failure Assessment (SOFA) score is now one of the most accepted score in critically ill
      patients and has been validated in general medico-surgical unit, as well as in trauma and
      cardiac surgery patients. It encompasses components assessing six organ functions. This score
      has also been shown to predict mortality in critically ill patients and in burn patients when
      used in a dynamic way.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ dysfunction as assessed by a change in the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or died).</measure>
    <time_frame>Seven days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length of stay</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free days of mechanical ventilation</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric intake</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>Seven days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete coverage defined as the time between admission and last surgery for grafting</measure>
    <time_frame>1, 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Second or Third Degree Burns</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% human albumin solution (HAS)</intervention_name>
    <description>Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:
≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; &lt; 10 gr/L: 150 g of 5% HAS.</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to the BICU in the Centre hospitalier de l'Université de Montréal
             within 24 hours following their thermal burn injury.

          2. Patients with second or third degree burns greater or equal than 20% of total body
             surface area.

          3. Patients aged 18 years or older. -

        Exclusion Criteria:

          1. Patients with serum albumin greater than 30 g/dl at the time of randomization.

          2. Patients with a do not resuscitate order.

          3. Patients needing total parenteral nutrition.

          4. Patients with the following chronic diseases that could affect baseline SOFA
             calculation or serum albumin levels: end-stage kidney disease, nephrotic syndrome,
             hepatitis, exudative enteropaty, chronic thrombocytopenia or hematological malignancy.

          5. Patients with a known reaction to albumin.

          6. Pregnant or lactating women.

          7. Patients younger than 18 years old. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Eljaiek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal - CHUM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc-Jacques Dubois, MD - FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal - CHUM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Eljaiek, MD</last_name>
    <phone>514 890-8000</phone>
    <phone_ext>15875</phone_ext>
    <email>roberto.eljaiek@umontreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Eljaiek, MD</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>15875</phone_ext>
      <email>roberto.eljaiek@umontreal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Marc-Jacques Dubois, MD - FRCPC</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>15875</phone_ext>
      <email>marc-jacques.dubois.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Marc-Jacques Dubois</investigator_full_name>
    <investigator_title>MD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>Hypoalbuminemia</keyword>
  <keyword>Burns</keyword>
  <keyword>Albumin</keyword>
  <keyword>Organ dysfunction</keyword>
  <keyword>Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
    <mesh_term>Hypoalbuminemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

